Antrodan, A β-glucan obtained from Antrodia cinnamomea mycelia, is beneficial to benign prostate hyperplasia

2015 ◽  
Vol 6 (2) ◽  
pp. 635-645 ◽  
Author(s):  
Chiung-Chi Peng ◽  
Yi-Ting Lin ◽  
Kuan-Chou Chen ◽  
Charng-Cherng Chyau ◽  
Robert Y. Peng
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Benign Prostate Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Common Disease ◽  
Prostate Hyperplasia ◽  
Antrodia Cinnamomea ◽  
Benign Prostate

Benign prostatic hyperplasia (BPH), one of the most common disease usually occurring in men in their 50s, has now become an atypical direct cause of mortality.

scholarly journals Periodontal disease and risk of benign prostate hyperplasia: a cross-sectional study

2019 ◽  
Vol 6 (1) ◽  
Author(s):  
Lan Wu ◽  
Bing-Hui Li ◽  
Yun-Yun Wang ◽  
Chao-Yang Wang ◽  
Hao Zi ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Periodontal Disease ◽  
Subgroup Analysis ◽  
Benign Prostate Hyperplasia ◽  
Prostate Volume ◽  
Prostatic Hyperplasia ◽  
Health Examination ◽  
Control Analysis ◽  
Prostate Hyperplasia ◽  
Benign Prostate

Abstract Background Both periodontal disease and benign prostatic hyperplasia are age-related diseases that affect millions of people worldwide. Hence, this study aimed to investigate the association between periodontal disease and the risk of benign prostatic hyperplasia. Methods A total of 4930 participants were selected from an available health examination that was carried out in 2017, only males were considered for further analysis. All eligible males were divided into benign prostatic hyperplasia and normal groups, the benign prostatic hyperplasia group was then divided into prostate volume ≤ 60 g and > 60 g subgroups; all their periodontal status was extracted and then into normal (CPI score of 0), periodontal disease (CPI score between 1 and 4), and periodontitis (CPI score between 3 and 4) groups. The correlation between periodontal disease and benign prostatic hyperplasia was investigated using logistic regression analyses and greedy matching case-control analysis. Subgroup analysis based on prostate volume was also performed. All analyses were conducted with SAS 9.4 software. Results A total of 2171 males were selected for this analysis. The presence of periodontal disease significantly increased the risk of benign prostatic hyperplasia by 1.68 times (OR = 1.68, 95% CI: 1.26–2.24), and individuals with periodontitis showed a higher risk (OR = 4.18, 95% CI: 2.75–6.35). In addition, among matched cases and controls, this association remained robust (periodontal disease: OR = 1.85, 95% CI: 1.30–2.64; periodontitis: OR = 4.83, 95% CI: 2.57–9.07). Subgroup analysis revealed that periodontal disease significantly increased benign prostate hyperplasia risk as well (for prostate volume ≤ 60 g: OR = 1.64, 95% CI: 1.22–2.20; for volume > 60 g: OR = 2.17, 95% CI: 1.04–4.53), and there was a higher risk in the group with a prostate volume greater than 60 g. Conclusion Periodontal disease is significantly and positively associated with an increased risk of benign prostatic hyperplasia. Further validation studies should be performed to explore the relationship between periodontal treatment and benign prostate hyperplasia.

scholarly journals The Significance of PSA/IGF-1 Ratio in Differentiating Benign Prostate Hyperplasia from Prostate Cancer

2000 ◽  
Vol 16 (3-4) ◽  
pp. 143-146 ◽  
Author(s):  
G. Koliakos ◽  
D. Chatzivasiliou ◽  
Th. Dimopoulos ◽  
V. Trachana ◽  
K. Paschalidou ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Roc Analysis ◽  
Benign Prostate Hyperplasia ◽  
Specific Antigen ◽  
Prostatic Hyperplasia ◽  
Prostate Hyperplasia ◽  
Patients With Cancer ◽  
Free Psa ◽  
Benign Prostate

The importance of insulin-like growth factor 1 (IGF-1) in human serum for the early diagnosis of prostate cancer is controversial. The IGF-1/PSA ratio may improve the performance of prostate specific antigen (PSA) as a prostate cancer marker. IGF-1, along with PSA and free PSA concentration, was measured in the serum of 34 patients with prostate cancer and in 131 patients with benign prostatic hyperplasia (BPH). Although IGF-1 concentration did not significantly differ between the groups, PSA/IGF-1 ratio could clearly distinguish the two groups. In patients with cancer but not in patients with BPH, IGF-1 concentration correlated with PSA and free PSA. The values of PSA and free PSA correlated with each other for both groups. Receivers Operating Curve (ROC) analysis indicated a better sensitivity to specificity ratio for PSA/IGF-1 than for PSA or Free/Total (F/T) PSA.

scholarly journals HIGH POWER TRANSURETHRAL THULIUM:YAG LASER VAPOENUCLEATION OF PROSTATE – A NEW STANDARD IN BENIGN PROSTATE HYPERPLASIA SURGERY

InterConf ◽  
2021 ◽  
pp. 281-289
Author(s):  
Alexei Plesacov ◽  
Ivan Vladanov ◽  
Vitalii Ghicavii
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
High Power ◽  
Benign Prostate Hyperplasia ◽  
Postoperative Recovery ◽  
Minimal Invasive ◽  
Prostatic Hyperplasia ◽  
Surgical Trauma ◽  
Prostate Hyperplasia ◽  
Invasive Techniques ◽  
Benign Prostate

According to current reccomandations, open adenomectomy is considered the most efficient surgical option for patients with large benign prostatic hyperplasia. In order to reduce surgical trauma and to improuve postoperative recovery, there have been proposed several minimally invasive techniques for the treatment of large benign prostatic hyperplasia, the most innovative being laser surgery. High power Thulium:YAG laser vapoenucleation of prostate is becoming popular for minimal invasive surgical management of benign prostate hyperplasia.

scholarly journals Study on Estimation of Serum Prostate Specific Antigen Level and Prostate Volume with Trans-Abdominal Ultrasonography Finding in Benign Prostate Hypertrophy at Tertiary Care Hospital : A Cross Sectional Descriptive Study

2021 ◽  
Vol 6 (2) ◽  
pp. 1556-1560
Author(s):  
Chandra Prakash Gaire
Keyword(s):  
Prostate Specific Antigen ◽  
Benign Prostate Hyperplasia ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Prostatic Hyperplasia ◽  
Prostate Specific Antigen Level ◽  
Age Group ◽  
Antigen Level ◽  
Prostate Hyperplasia ◽  
Benign Prostate

Introduction: The periurethral and transition zones of the prostatic gland develop benign prostatic hyperplasia and represent an inevitable phenomenon for the ageing male population. Prostatic specific antigen, is a serine protease, level rises in the blood if the barrier between thelining epithelium and the blood stream is damaged. Benign prostatic hyperplasia, prostatic carcinoma and prostatitis are three common diseases where PSA in the serum is raised. Prostate volume also increases according to age, which can be estimated by trans-abdominal ultrasonography. Objective: The aim of the study is to estimate the PSA level in blood and its relationship with prostate volume in benign prostatic hyperplasia patients. Methodology: It is a descriptive cross-sectional study which was carried out between a periods of 1st April 2018 to 31st March 2019 at Birat Medical College Teaching Hospital. All the patients diagnosed with benign prostate hyperplasia at the department of urology were included in the study. Blood samples of patients were analyzed for Prostate specific antigen level estimation by chemiluminescence immunosorbent assay. Prostatic volume of the patients was measured by Transabdominal ultrasound technique. Data were entered and analyzed in Microsoft Excel. Results: A total of 68 patients were diagnosed with benign prostate hyperplasia. The mean age of the patients was 61.8±12.3 years. The maximum number 23 of patients with BPH was there in age group 51-60. The maximum no of patients 38 were having their PSA level between the range of 4.0-10.0 ng/ml. The maximum no of patients 28 was having Prostate volume in the range of 40-60 gm. The maximum number of patients 31 was having diabetes mellitus as a co-morbid association. The maximum mean PSA level and prostate volume in the patients were observed in age group >80 years,which was 20.1±8.6 ng/ml and >80 gm respectively. Conclusion: The prostate specific antigen level and prostate volume both increase in advance age group of patients suffering with benign prostate hyperplasia.

Holmium laser enucleation of prostate for patients with acute urinary retention due to benign prostate hyperplasia: Efficacy and safety

2019 ◽  
Author(s):  
Pu Li(Former Corresponding Author) ◽  
Jun Tao ◽  
Chengming Wang ◽  
Min Tang ◽  
Xiaoxin Meng(New Corresponding Author)
Keyword(s):  
Urinary Retention ◽  
Acute Urinary Retention ◽  
Benign Prostate Hyperplasia ◽  
Holmium Laser ◽  
Common Disease ◽  
Urinary Flow ◽  
Prostate Hyperplasia ◽  
Laser Enucleation ◽  
Benign Prostate ◽  
Holmium Laser Enucleation

Abstract Background Benign prostate hyperplasia (BPH) is a common disease in older men, and part of patients develop acute urinary retention (AUR) at the time of initial treatment. The aim of this study was to evaluate the effectiveness and safety of holmium laser enucleation of prostate (HoLEP) for patients with BPH in setting of AUR. Methods The clinical data of 88 patients with BPH who underwent HoLEP surgery in our center were retrospectively analyzed. AUR existed in 34 patients and the other 54 patients had no AUR. The general information, prostate volume, urodynamic parameters and intraoperative parameters were recoeded and compared. The outcome were recorded and analysed including the international prostate symptom score (IPSS), quality of life score (QoL), maximum urinary flow rate (Qmax), and post-voiding residual (PVR). Results In both groups, the preoperative parameters were equivalent except for the white blood cell in urinalysis. All the HoLEP procedures were smoothly carried out. The intr- and post-operative complications were low in both groups and no difference were detected. All the patients were followed up for at least 6 months. IPSS, QoL, Qmax and PVR were all improved in both groups. No statistical differences were obtained in these parameters between groups. Conclusion s HoLEP could be a safe and effective treatment for BPH patients either with or without AUR. The efficacy was immediate and sustained during the short-term follow-up session in both groups.

Evaluating how much dutasteride actually reduces serum dihydrotestosterone level: A Reconsideration based on unexpected results from a study of treatment of benign prostatic hyperplasia with dutasteride

2020 ◽  
pp. 205141582092630
Author(s):  
Masanori Nukui
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Sex Hormones ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Prostatic Hyperplasia ◽  
Level Of Evidence ◽  
Prostate Hyperplasia ◽  
Natural Decrease ◽  
One Year ◽  
Benign Prostate

Objective: This study aimed to evaluate the effect of dutasteride treatment of benign prostatic hyperplasia on serum steroidal sex hormones and prostate volume (PV). Methods: Thirty patients with benign prostate hyperplasia treated with dutasteride for one year were assessed for changes in PV and serum sex hormones (testosterone (T), dihydotestosterone (DHT), estradiol (E2) and dehydroepiandrosterone sulphate (DHEAS)). PV was measured by ultrasonography. A paired or unpaired t-test and Pearson’s correlation coefficient test were used for statistical analysis. Results: DHT and DHEAS decreased by 38.5% and 20.3%, respectively. On the contrary, T and E2 increased by 34.3% and 9.4%, respectively. PV and prostate-specific antigen decreased by 17.7% and 63.4%, respectively. The rate of decrease of DHT had a negative correlation with PV, and the rate of decrease of DHEAS had positive correlation with PV. Conclusion: DHT did not decrease as expected (previous studies showed a decrease of approximately 90%). However, DHEAS decreased more than a natural decrease. It is possible that the conversion from DHEAS to DHT, via the conversion to T, in the prostate was accelerated by the decrease of DHT, especially in larger prostates. However, this discrepancy cannot be full explained by the conversion from DHEAS to DHT, as mentioned above. Level of evidence: Level 2c

scholarly journals Picture Of Age Factors And Sexual Activity With The Incidence Of Benign Prostate Hyperplasia

2017 ◽  
Vol 1 (2) ◽  
pp. 16-25
Author(s):  
Hamdana ◽  
Fatmawati
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Sexual Activity ◽  
Sampling Method ◽  
Age Factors ◽  
Prostatic Hyperplasia ◽  
Benign Disease ◽  
Prostate Hyperplasia ◽  
Descriptive Approach ◽  
The Right ◽  
Benign Prostate

In Indonesia Prostate Hyperplasia Benigna Based on the autopsy rate of microscopic changes at the age of 30-40 years. When microscopic changes develop, anatomic pathologic changes occur in men aged 50 years, the incidence rate is around 50%. 80 years old around 80% and 90 years old 100%. Prevalence increases because of an increase in life expectancy. The results of a survey conducted on Benigna Prostate Hyperplasia patients at H. Andi Sulthan Daeng Radja Hospital in Bulukumba District, patients with Benigna Prostate Hyperplasia have an average age of> 50 years as many as 30 people. This study aims to determine the description of age and sexual activity with the incidence of hyperplasia prostate benign disease in H. Andi Sulthan Daeng Radja District Hospital. This study uses a descriptive approach with a population of 30 and is sampled. Sampling using the Total Sampling method. The results of research on the incidence of prostate hyperplasia benign disease mostly occur with age and partial sexual activity who experience benign prostatic hyperplasia more normal sexual activity 1-2 times/weeks and only a few are abnormal sex frequency. The conclusion of the study is the age category of the initial elderly as many as 7 people (23.3%), the final elderly as many as 8 people (26.7%). While the age of seniors as many as 15 people (50%) the category of normal sex frequency <3 times/week as many as 16 respondents (53.3%) and as many as 14 respondents (46.7%) who do sexual frequency> 3 times a week. The suggestion from this research is that it should pay attention to various aspects that can influence the occurrence of hyperplasia prostate benign in patients so that its incidence can be prevented and can provide good service, as well as the right action for sufferers of benign prostatic hyperplasia.

scholarly journals A 87 YEARS OLD MALE WITH GIANT PROSTATIC HYPERPLASIA AND BLADDER STONES, THE LARGEST PROSTATE REPORTED IN INDONESIA

2017 ◽  
Vol 24 (2) ◽  
Author(s):  
Vera Vera ◽  
Sawkar Vijay Pramod
Keyword(s):  
Body Mass Index ◽  
Benign Prostate Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Chief Complaint ◽  
Median Lobe ◽  
Prostate Hyperplasia ◽  
Case Presentation ◽  
Prostate Weight ◽  
Large Prostate ◽  
Benign Prostate

Objective: The aim of this article is to report a case of Giant Prostatic Hyperplasia and see the correlation between volume of prostate and benign prostate hyperplasia (BPH) symptoms. Giant BPH is defined as a prostate weight over 200 g or 500 g; the lower threshold was suggested by Japanese authors. It’s extremely rare, with only 16 cases exceeding 500 g till 2013. Case presentation: Patient was an 87-year-old male with chief complaint of haematuria. We performed Transabdominal Ultra Sonography (USG) on the patient. Discussion: Transabdominal USG showed enlarged prostate with median lobe protruding into the bladder measuring 86 x 102 x 76 mm and 348 cc in volume. We performed transvesical prostatectomy. The large prostate was enucleated completely in one piece with 23 stones measuring about 1 cm in size. Grossly, the mass measured 12 x 8 cm and weighed 300 g. Histopathology evaluation revealed BPH. Conclusion: To our knowledge, this is the first giant BPH case being reported in Indonesia. We would like to emphasize that severity of BPH symptoms does not correlate with volume of the prostate. Unfortunately, we can not conclude that there were correlation between body mass index (BMI) and volume due to lack of BMI data from the literature.

Chronobiological approach to the treatment of patients with benign prostate hyperplasia and chronic prostatitis: results of a morphological examination

2021 ◽  
Vol 11 (2) ◽  
pp. 113-122
Author(s):  
Andrey V. Kuzmenko ◽  
Timur A. Gyaurgiev ◽  
Ivan I. Barannikov ◽  
Boris E. Leybovich
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Standard Therapy ◽  
Chronic Prostatitis ◽  
Inflammatory Process ◽  
Comparison Group ◽  
Prostatic Hyperplasia ◽  
Morphological Examination ◽  
Prostate Hyperplasia ◽  
The Individual ◽  
Benign Prostate

MATERIALS AND METHODS: 60 patients with benign prostatic hyperplasia (BPH) and category II chronic prostatitis (NIH, 1995) were examined. The average age of the patients was 60.55.5 years. The patients were divided into two groups of 30 people each. The comparison group (GC) included patients who received standard therapy with drugs from the group of alpha-blockers and fluoroquinolones. The main group (MG) consisted of patients who received standard therapy in combination with physiotherapy sessions with the device SMART-PROST, which were carried out in the acrophase of the chronorhythm. After the end of the course of therapy all patients underwent transurethral resection of the prostate, after which a morphological and morphometric (immunohistochemical) study of the obtained material was carried out. RESULTS: According to the results of the morphological and morphometric examination of the histological material in patients of the CG and MG, statistically significant differences were revealed in all the studied parameters, which testify to the persistence of signs of the inflammatory process in the CG, while in the MG, the severity of inflammation was significantly lower. CONCLUSION: According to the results of the study, personalized complex therapy of patients with benign prostatic hyperplasia in combination with chronic prostatitis using a combined physiotherapeutic effect of the SMART-PROST device, taking into account the individual chronobiological characteristics of patients, allows to more effectively arrest the inflammatory process in the prostate tissue, which can lead to a decrease in the number of postoperative complications. However, the last statement requires further more detailed study.

Use of laser technologies in surgical treatment of benign prostate hyperplasia

2021 ◽  
pp. 36-45
Author(s):  
Mark Albertovich Volodin ◽  
Evgeny Nikolaevich Bolgov ◽  
Maya A. Kuzmina ◽  
Darya Dmitrievna Vasina
Keyword(s):  
Surgical Treatment ◽  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Surgical Instruments ◽  
Prostate Hyperplasia ◽  
Minimum Diameter ◽  
Surgical Interventions ◽  
Laser Technologies ◽  
Laser Devices ◽  
Benign Prostate

The use of laser technology in the surgical treatment of patients with benign prostatic hyperplasia has recently become widespread and introduced into practice. This area of surgery uses a large range of laser modifications and methods of their application when performing surgical interventions on the prostate. The article discusses laser devices for minimally invasive operations on patients with benign prostatic hyperplasia in comparison with traditional methods of BPH surgical treatment. The advantages of using laser technologies include the reduction of the time of surgical intervention, the decrease in the number of traumatic complications and bleeding, the absence of the damaging effect of the shock wave, the possibility of using it with surgical instruments of the minimum diameter, and the possibility of using it with flexible surgical instruments.

Sign in / Sign up

Export Citation Format

Share Document